HK1085771A1 - High affinity anti-human ige antibodies - Google Patents

High affinity anti-human ige antibodies

Info

Publication number
HK1085771A1
HK1085771A1 HK06107957.0A HK06107957A HK1085771A1 HK 1085771 A1 HK1085771 A1 HK 1085771A1 HK 06107957 A HK06107957 A HK 06107957A HK 1085771 A1 HK1085771 A1 HK 1085771A1
Authority
HK
Hong Kong
Prior art keywords
high affinity
ige antibodies
human ige
affinity anti
human
Prior art date
Application number
HK06107957.0A
Other languages
English (en)
Inventor
Sanjaya Singh
Catherine Foster
Herren Wu
Original Assignee
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanox Inc filed Critical Tanox Inc
Publication of HK1085771A1 publication Critical patent/HK1085771A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
HK06107957.0A 2003-02-01 2006-07-17 High affinity anti-human ige antibodies HK1085771A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44422903P 2003-02-01 2003-02-01
PCT/US2004/002894 WO2004070011A2 (fr) 2003-02-01 2004-02-02 Anticorps ige anti-humains a affinite elevee

Publications (1)

Publication Number Publication Date
HK1085771A1 true HK1085771A1 (en) 2006-09-01

Family

ID=32850839

Family Applications (3)

Application Number Title Priority Date Filing Date
HK06107957.0A HK1085771A1 (en) 2003-02-01 2006-07-17 High affinity anti-human ige antibodies
HK09104910.0A HK1126788A1 (zh) 2003-02-01 2009-06-01 高親合力的抗人類 抗體
HK12106994.9A HK1166330A1 (zh) 2003-02-01 2012-07-17 產生高親和力抗體的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK09104910.0A HK1126788A1 (zh) 2003-02-01 2009-06-01 高親合力的抗人類 抗體
HK12106994.9A HK1166330A1 (zh) 2003-02-01 2012-07-17 產生高親和力抗體的方法

Country Status (16)

Country Link
US (4) US7531169B2 (fr)
EP (4) EP1592776A4 (fr)
JP (4) JP4764334B2 (fr)
CN (3) CN1829806A (fr)
AU (3) AU2004209637A1 (fr)
CA (2) CA2514840C (fr)
CY (2) CY1118063T1 (fr)
DK (2) DK2407485T3 (fr)
ES (2) ES2566778T3 (fr)
HK (3) HK1085771A1 (fr)
HU (2) HUE028458T2 (fr)
IL (1) IL176940A (fr)
MX (1) MX338940B (fr)
PT (1) PT2000481E (fr)
SI (2) SI2000481T1 (fr)
WO (2) WO2004070010A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060234296A1 (en) * 2003-02-01 2006-10-19 Sanjaya Singh Method for generating high affinity antibodies
ES2566778T3 (es) * 2003-02-01 2016-04-15 Tanox, Inc. Anticuerpos anti-IgE de humano de alta afinidad
JP4943161B2 (ja) 2003-12-23 2012-05-30 ジェネンテック， インコーポレイテッド 新規抗ｉｌ１３モノクローナル抗体での癌の処置
SG183683A1 (en) * 2004-02-02 2012-09-27 Tanox Inc Identification of novel ige epitopes
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006055704A2 (fr) * 2004-11-17 2006-05-26 Curagen Corporation Anticorps diriges contre des proteines ten-m et utilisations associees
AU2006297304B2 (en) * 2005-09-29 2012-05-17 Medimmune, Llc Method of identifying membrane LG specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
DE102007052281A1 (de) * 2007-11-02 2009-05-07 Zenteris Gmbh Einschritt-Multiplex-Immuntest
US20100248971A1 (en) 2007-12-03 2010-09-30 Takashi Inagaki Process for antibody production
US20130338038A1 (en) 2007-12-21 2013-12-19 Pdl Biopharma, Inc. Method of screening complex protein libraries to identify altered properties
CN101230103B (zh) * 2008-03-25 2011-09-07 中国医药集团总公司四川抗菌素工业研究所 一全人源重组抗-IgE抗体
EP2853545B8 (fr) 2008-09-17 2023-04-05 Xencor, Inc. Anticorps spécifique pour IgE
US9187568B2 (en) 2009-05-07 2015-11-17 Stallergenes S.A. Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route
EP2494356B1 (fr) 2009-10-26 2017-03-15 Genentech, Inc. Essais pour détecter des anticorps spécifiques d'anticorps anti-ige thérapeutiques et leur utilisation en anaphylaxie
JP2013523153A (ja) * 2010-04-07 2013-06-17 アッヴィ・インコーポレイテッド ＴＮＦ−α結合タンパク質
AR089434A1 (es) 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
WO2013116287A1 (fr) 2012-01-31 2013-08-08 Genentech, Inc. ANTICORPS ANTI-IgE SE LIANT À M1' ET LEURS PROCÉDÉS D'UTILISATION
BR112014028600B1 (pt) 2012-05-18 2022-11-22 Genentech, Inc Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
ES2900342T3 (es) 2012-08-21 2022-03-16 Sanofi Biotechnology Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US10196458B2 (en) 2013-07-26 2019-02-05 The Regents Of The University Of California Anti-immunoglobulin E antibodies and methods of using thereof
CN106471372B (zh) 2014-01-29 2019-10-11 通用电气健康护理生物科学股份公司 用于相互作用分析的方法和***
CN106062000B (zh) 2014-02-28 2021-05-28 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗皮肤感染的方法
CA2943588C (fr) * 2014-06-17 2019-04-30 Academia Sinica Anticorps humanises anti-ige qui reticulent cd23 sur des lymphocytes b mais qui ne sensibilisent pas les mastocytes
CN107074933B (zh) * 2014-10-24 2021-03-19 豪夫迈·罗氏有限公司 基于vh-vl域间角的抗体人源化
CN107206073A (zh) 2014-11-14 2017-09-26 赛诺菲生物技术公司 通过施用il‑4r拮抗剂用于治疗伴随鼻息肉的慢性鼻窦炎的方法
MA46098A (fr) 2016-09-01 2019-07-10 Regeneron Pharma Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
JP2020503316A (ja) 2016-12-22 2020-01-30 ジェネンテック， インコーポレイテッド 凍結乾燥ポリペプチドの再構成時間を低減するための方法及び製剤
WO2018129248A1 (fr) 2017-01-06 2018-07-12 The Regents Of The University Of California Anticorps anti-ige thérapeutiques et méthodes et compositions associées
WO2019028367A1 (fr) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de l'oesophagite à éosinophiles active
CA3079946A1 (fr) 2017-10-30 2019-05-09 Sanofi Biotechnology Methodes de traitement ou de prevention de l'asthme par administration d'un antagoniste d'il-4r
SG11202007564VA (en) 2018-02-09 2020-09-29 Genentech Inc Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
CN112203724A (zh) 2018-03-26 2021-01-08 诺华股份有限公司 使用利格珠单抗治疗慢性自发性荨麻疹的方法
EP3793597A1 (fr) 2018-05-13 2021-03-24 Regeneron Pharmaceuticals, Inc. Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
CN109651510B (zh) * 2018-12-04 2023-03-24 上海长征医院 抗Eno1抗体及其用途
AU2020240132A1 (en) 2019-03-21 2021-09-16 Regeneron Pharmaceuticals, Inc. Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
GB2589049C (en) 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
CA3147068A1 (fr) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methodes de traitement de l'allergie et d'amelioration de l'immunotherapie specifique aux allergenes par administration d'un antagoniste de l'il-4r
JP2021141861A (ja) * 2020-03-13 2021-09-24 富士フイルム和光純薬株式会社 抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法
WO2021255621A1 (fr) 2020-06-15 2021-12-23 Novartis Ag Traitement d'allergie alimentaire à l'aide d'anticorps anti-ige
EP4355362A1 (fr) 2021-06-14 2024-04-24 Novartis AG Formulation pharmaceutique contenant des anticorps anti-ige
WO2023111811A1 (fr) 2021-12-14 2023-06-22 Novartis Ag Traitement de réactions allergiques à l'aide d'anticorps anti-ige

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268176A (en) * 1916-11-29 1918-06-04 Us Slicing Machine Co Power mechanism for slicing-machines.
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5428133A (en) * 1987-12-31 1995-06-27 Tanox Biosystems, Inc. Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils
US5449760A (en) 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US5614611A (en) * 1987-12-31 1997-03-25 Tanox Biosystems, Inc. Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils
DE122006000007I1 (de) 1987-12-31 2006-04-27 Tanox Biosystems Inc Antigene epitope, die sich ausschlisslich auf ige-tragenden B-Lymphocyten befinden.
US5091313A (en) * 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
ES2113940T3 (es) * 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
WO1992017207A1 (fr) * 1991-03-26 1992-10-15 Tanox Biosystems, Inc. ANTICORPS MONOCLONAUX QUI SE LIENT A L'IgE SECRETEE ET LIEE AUX MEMBRANES MAIS QUI NE SE LIENT PAS A L'IgE SE TROUVANT SUR LES LEUCOCYTES BASOPHILES
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
MX9305070A (es) 1992-08-21 1994-04-29 Genentech Inc Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
DE69333484T2 (de) * 1992-09-24 2005-03-24 Novartis Ag Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp
US5958708A (en) * 1992-09-25 1999-09-28 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US6066718A (en) * 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
CA2149329C (fr) 1992-11-13 2008-07-15 Darrell R. Anderson Utilisation d'anticorps hybrides et radioisotopiques diriges contre l'antigene de restriction de la differenciation des lymphocytes b humains pour le traitement du lymphome b
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
AU2103699A (en) * 1998-01-29 1999-08-16 Tse Wen Chang Treating atopic dermatitis with ige antagonists
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US20060234296A1 (en) * 2003-02-01 2006-10-19 Sanjaya Singh Method for generating high affinity antibodies
US20050169909A1 (en) * 2004-02-02 2005-08-04 Sanjaya Singh Identification of novel IgE epitopes
ES2566778T3 (es) * 2003-02-01 2016-04-15 Tanox, Inc. Anticuerpos anti-IgE de humano de alta afinidad

Also Published As

Publication number Publication date
MX338940B (es) 2016-05-06
HK1166330A1 (zh) 2012-10-26
EP1592777A2 (fr) 2005-11-09
US20140295494A1 (en) 2014-10-02
JP2011042654A (ja) 2011-03-03
US20130052202A1 (en) 2013-02-28
CN1829806A (zh) 2006-09-06
AU2011202021A1 (en) 2011-05-26
IL176940A (en) 2015-11-30
HUE028458T2 (en) 2016-12-28
IL176940A0 (en) 2006-12-10
CA2514839A1 (fr) 2004-08-19
US9156908B2 (en) 2015-10-13
DK2000481T3 (en) 2016-06-06
CY1118063T1 (el) 2017-06-28
HK1126788A1 (zh) 2009-09-11
ES2566778T3 (es) 2016-04-15
HUE028407T2 (hu) 2016-12-28
EP1592776A4 (fr) 2008-06-04
CN102993306A (zh) 2013-03-27
JP2011217747A (ja) 2011-11-04
JP4764334B2 (ja) 2011-08-31
CN102993306B (zh) 2015-01-28
WO2004070010A3 (fr) 2005-12-08
WO2004070011A3 (fr) 2005-11-24
EP1592777A4 (fr) 2008-06-04
US20110064725A1 (en) 2011-03-17
EP2407485A1 (fr) 2012-01-18
US20060251644A1 (en) 2006-11-09
ES2575547T3 (es) 2016-06-29
SI2407485T1 (sl) 2016-09-30
CA2514840C (fr) 2017-11-07
AU2004209638A1 (en) 2004-08-19
US7531169B2 (en) 2009-05-12
CN1771338B (zh) 2012-10-17
US8604171B2 (en) 2013-12-10
AU2004209638B2 (en) 2011-02-03
AU2004209637A1 (en) 2004-08-19
EP2407485B1 (fr) 2016-01-27
CN1771338A (zh) 2006-05-10
WO2004070010A2 (fr) 2004-08-19
US8252284B2 (en) 2012-08-28
EP2000481A1 (fr) 2008-12-10
AU2011202021B2 (en) 2013-08-29
SI2000481T1 (sl) 2016-08-31
WO2004070011A2 (fr) 2004-08-19
CA2514840A1 (fr) 2004-08-19
JP2006516408A (ja) 2006-07-06
EP1592776A2 (fr) 2005-11-09
EP2000481B1 (fr) 2016-03-30
DK2407485T3 (en) 2016-03-21
PT2000481E (pt) 2016-06-17
CY1117617T1 (el) 2017-04-26
JP5296138B2 (ja) 2013-09-25
JP2006516409A (ja) 2006-07-06

Similar Documents

Publication Publication Date Title
HK1166330A1 (zh) 產生高親和力抗體的方法
IL243914A0 (en) Antibodies against vegf
PT1599504E (pt) Anticorpo modificado
EP1616881A4 (fr) Anticorps anti-mpl
EP1494693A4 (fr) Anticorps specifiques au cripto
IL175608A0 (en) Antibodies
PL375405A1 (en) Antibodies
EP1648512A4 (fr) Anticorps anti-cd19
IL173557A0 (en) Variable antibodies
EP1653801A4 (fr) Anticorps modifies presentant une affinite de liaison a l'antigene amelioree
AU2003264009A8 (en) Humanized rabbit antibodies
HK1087722A1 (en) Interleukin-10 antibodies
EP1499352A4 (fr) Anticorps anti-interleukine-9 recombinants
TWI346203B (en) Antibody pair screening methods
EP1699485A4 (fr) Anticorps anti-hydroxylase et utilisations
IL172510A0 (en) Antibodies and uses thereof
EP1633399A4 (fr) Anticorps recombines, compositions et leurs methodes de fabrication et d'utilisation
GB0306618D0 (en) Antibody
GB0226878D0 (en) Antibodies
HK1209139A1 (en) Modified antibody
GB0317974D0 (en) Novel antibodies
GB0329711D0 (en) Antibodies
GB0217742D0 (en) Novel antibodies
GB0203018D0 (en) Antibodies
GB0218234D0 (en) Antibodies

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20240201